OS Therapies (NYSE American: OSTX) is addressing the urgent need for innovative therapies to kill aggressive cancers that express HER2, including osteosarcoma—a rare and often fatal bone cancer—as well as other solid...
The nonprofit organization Healing the Hero is bringing hope to U.S. military personnel, veterans, first responders, and Gold Star Families by leveraging neurolinguistic programming (NLP)-informed methods to directly...
Closely held Siloton is developing a patented miniaturized medical imaging platform that combines photonic chips with optical coherence tomography (OCT) to detect and monitor a range of prevalent ophthalmic diseases...
Closely held Pacylex Pharmaceuticals is developing a first-in-class oral cancer therapy with a novel, broad mechanism of action designed for refractory cancers as both a monotherapy and a future combination therapy.
Closely held illumiSonics is addressing a significant unmet medical need by redefining tissue imaging with its proprietary multi-laser imaging (MLI) platform, an advanced modality designed for life sciences research...
Adagio Medical (NASDAQ: ADGM) is innovating catheter ablation technologies for the treatment of one of the most challenging and underserved areas in electrophysiology—ventricular tachycardia (VT), a dangerous type of...
Niagen Bioscience (NASDAQ: NAGE) is pioneering the research and development of nicotinamide adenine dinucleotide (NAD+)—a vital coenzyme essential to cellular metabolism, energy production, and DNA repair that declines...
MAIA Biotechnology (NYSE American: MAIA) is focusing on the development and commercialization of breakthrough telomere-targeting immunotherapies: potential first-in-class drugs with novel mechanisms of action that aim...
Closely held Cell Technologies is advancing regenerative medicine through proprietary autologous and allogeneic stem cell platforms designed to treat the pain and inflammation associated with osteoarthritis (OA) and...
Closely held PolarityBio is developing investigational regenerative biologics for chronic wound healing, targeting some of the most refractory wounds in medicine. The company’s lead program and first entry into the...
Closely held Casp-Aid is advancing a differentiated therapeutic strategy aimed at repairing damaged neurons responsible for cognitive impairment by targeting the root cause of neuronal damage in Alzheimer disease (AD)...
MediWound (NASDAQ: MDWD) is advancing a proprietary enzymatic platform derived from bromelain, a proteolytic enzyme extracted from pineapple stems. The company’s non-surgical approach to necrotic tissue removal has...
Closely held Imviva Biotech is advancing a next-generation approach to cell therapy designed to overcome some of the most persistent barriers facing allogeneic CAR-T development. By combining proprietary gene editing...
Closely held Astrocyte Pharmaceuticals is developing a new category of neuroprotective therapies aimed at reducing early brain damage following stroke, concussion, and traumatic brain injury (TBI). By harnessing the...
Closely held First Ascent Biomedical is working to redefine how oncologists select therapies by pairing genomics with a proprietary live-cell testing platform that evaluates how an individual patient’s cancer responds...
For more than two decades, Slone Partners has maintained a dedicated focus on leadership recruitment for life sciences and healthcare organizations. The company’s co-CEO and managing partner, Leslie Loveless, has been...
PetVivo Holdings (PetVivo Animal Health) (OTCQX: PTEV; OTCID: PETVW) is adapting human regenerative therapies for the management of osteoarthritis (OA) and other joint disorders in companion and athlete animals. The...
Closely held Aqua Medical is advancing therapy for gastrointestinal (GI) and metabolic diseases—including Type 2 diabetes—using its disruptive, transoral, outpatient vapor-based endoscopic ablation platform.
Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) is emerging as a leader in the development of anti-inflammatory and anti-fibrotic medicines designed to counteract the fundamental biological processes that drive...
Trevi Therapeutics (NASDAQ: TRVI) is advancing a fundamentally different approach to the treatment of chronic cough—a high unmet need that significantly affects the quality of life for millions of Americans.
Closely held Experity Health is shaping the future of healthcare by embedding AI into urgent care hubs across the U.S. to improve patient access, speed clinical visits, and elevate care quality.
Immuneering (NASDAQ: IMRX) is challenging conventional approaches of sustained inhibition in oncology by pioneering a novel class of therapies designed to outsmart cancer’s ability to adapt. With a proprietary platform...